Leaflet: information for the user
Carvedilol cinfa 6.25 mg tablets EFG
Read this leaflet carefully before you start taking this medicine, because it contains important information for you.
Carvedilol cinfacontains carvedilol as the active ingredient, whichbelongs to a group of medicationsknown asalpha and beta blockers. Carvedilol has antioxidant, antihypertensive (blood pressure reduction), vasodilatory, and antianginal properties. It also reduces cardiac output, and has favorable effects on blood circulation at the heart level.
Carvedilol is indicated for the treatment of:
Do not take Carvedilol cinfa
Warnings and precautions
Consult your doctor or pharmacist before starting to take Carvedilol cinfa.
Inform your doctor if you have any of the following conditions:
Use in athletes
This medication contains carvedilol, which may produce a positive result in doping control tests.
Children and adolescents
Carvedilol is not recommended for use in children and adolescents under 18 years due to insufficient safety and efficacy data.
Carvedilol cinfa with other medications
Inform your doctor or pharmacist if you are taking, have taken recently, or may need to take any other medication.
This is very important, as taking multiple medications at the same time may increase or decrease their effect.
Do not take carvedilol with any other medication unless your doctor has permitted it.
These instructions may also apply to medications that have been used before or may be used after.
It is essential to inform your doctor if you are taking or have taken recently any of the following medications:
Carvedilol cinfa with food, drinks, and alcohol
Avoid taking Carvedilol cinfa simultaneously or immediately after taking grapefruit or grapefruit juice. Grapefruit or grapefruit juice may cause an increase in the active ingredient carvedilol in the blood and lead to unpredictable adverse effects.
Avoid excessive and simultaneous or occasional consumption of alcohol, as alcohol may affect the effect of Carvedilol cinfa.
Your doctor or pharmacist will inform you about the foods with which it is recommended to take the medication.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, or if you think you may be pregnant, consult your doctor or pharmacist before using this medication.
Pregnancy
Carvedilol is not recommended during pregnancy and lactation.
Carvedilol may cause fetal death in the womb, as well as premature birth. Additionally, adverse effects may occur in the fetus and newborn. After birth, the newborn has a higher risk of heart and lung problems.
Breastfeeding
Carvedilol passes into breast milk, so it is not recommended to use it during breastfeeding.
Driving and operating machinery
In some cases, this medication may impair your ability to drive or operate machinery. This is especially true when starting or changing treatment and when taking it with alcohol.
This medication contains saccharose and lactose.If your doctor has told you that you have an intolerance to certain sugars, consult with them before taking this medication.
Follow exactly the administration instructions of this medication as indicated by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist again.
Essential Hypertension
Adults
Oral route. The recommended starting dose is 12.5 mg once a day for the first two days. Subsequently, the recommended dose is 25 mg of carvedilol once a day. If necessary, your doctor may increase the dose you receive (at intervals of at least two weeks), up to 50 mg once a day or in two doses of 25 mg each.
Older Patients
Oral route. The recommended starting dose is 12.5 mg once a day, which is usually sufficient. If the response is not adequate, your doctor will adjust the dose (at intervals of at least two weeks).
Ischemic Cardiopathy
Adults
Oral route. The recommended starting dose is 12.5 mg twice a day (total 25 mg per day) for the first two days. Subsequently, the recommended dose is 25 mg twice a day (total 50 mg per day). If necessary, your doctor may increase the dose you receive (at intervals of at least two weeks), up to 50 mg twice a day (total 100 mg per day).
Older Patients
Oral route. The maximum recommended dose for older patients is 50 mg administered in divided doses (twice a day).
Chronic Heart Failure Treatment
Adults and Older Patients
Oral route
Your doctor will tell you individually the dose you should take, closely monitoring you during the adjustment to higher doses.
In case you are using heart disease medications (digitalis) or blood pressure control medications (diuretics and/or ACE inhibitors) and before starting carvedilol treatment, your doctor will adjust the amount of these types of medications you should take.
In any case, the recommended starting dose for carvedilol treatment in chronic heart failure is 3.12 mg twice a day (total 6.25 mg per day) for two weeks. If you tolerate this dose well, it can be increased subsequently (at intervals of at least two weeks) up to 6.25 mg twice a day (total 12.5 mg per day).
Your doctor may prescribe higher doses of carvedilol subsequently (at least two weeks after).
If you weigh less than 85 kg, the maximum recommended dose is 25 mg twice a day (total 50 mg per day). If your weight is greater than 85 kg, the maximum recommended dose is 50 mg twice a day (total 100 mg per day).
Your doctor will indicate the duration of your carvedilol treatment.
As a general rule, regardless of your disease, carvedilol withdrawal should be done gradually over a few days, or reduce the dose by half every three days.
Use in Children and Adolescents
Carvedilol is not recommended for use in children and adolescents under 18 years due to the lack of sufficient data on safety and efficacy.
Guidelines for Correct Administration
Take the tablets with a sufficient amount of liquid, a glass of water.
If you have congestive heart failure (your heart has lost a little of its ability to pump blood and may produce difficulty breathing, weakness, and fluid accumulation), you should take carvedilol while eating, to avoid the sensation of dizziness when standing up.
Remember to take your medication.
The tablet can be split into equal doses.
If You Take More Carvedilol Cinfa Than You Should
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone 91 562 04 20, indicating the medication and the amount ingested. It is recommended to bring the packaging and the medication leaflet to the healthcare professional.
If You Forget to Take Carvedilol Cinfa
Do not take a double dose to compensate for the missed doses.
If You Interrupt Treatment with Carvedilol Cinfa
Carvedilol treatment should not be interrupted abruptly, especially if you have ischemic cardiopathy, a disease that causes the heart not to pump blood well. Your doctor will gradually reduce the dose over a few days until you stop taking carvedilol completely.
If you have any other doubts about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everyone will experience them.
Side effects are classified as: very common (may affect more than 1 in 10 patients), common (may affect up to 1 in 10 patients), uncommon (may affect up to 1 in 100 patients), rare (may affect up to 1 in 1,000 patients), very rare (may affect up to 1 in 10,000 patients) and unknown frequency (cannot be estimated from available data).
Infections and infestations
Common:Bronchitis, pneumonia, upper respiratory tract infections, urinary tract infections.
Nervous system disorders
Very common:Headache, dizziness, and weakness, which are usually mild and occur mainly at the beginning of treatment.
Common:Presyncope, syncope (fainting), especially at the beginning of treatment.
Uncommon:Paresthesias (tingling sensation).
Mental and behavioural disorders
Common:Depressed mood, depression.
Uncommon:Sleep disorders.
Unknown frequency:Hallucinations.
Cardiac disorders
Very common:Worsening of heart failure (the heart has lost some of its ability to pump blood).
Common:Bradyarrhythmia (decreased heart rate), fluid overload, increased blood volume in the body.
Uncommon:Atrioventricular (AV) block (heart problems), and angina pectoris (chest pain).
Unknown frequency:Sinus arrest (a condition that makes heartbeats very slow or stop), especially in elderly patients or patients with other heart rhythm problems.
Vascular disorders
Very common:Low blood pressure.
Common:Postural hypotension (dizziness when standing up or changing body position), peripheral circulation disorders (cold hands and feet), worsening of symptoms in patients with intermittent claudication (increased pain in the legs when walking) or Raynaud's phenomenon (decreased blood flow to fingers and toes, ears, and nose), hypertension.
Respiratory, thoracic and mediastinal disorders
Common:Asthma and breathing difficulties in predisposed patients, fluid accumulation in the lungs.
Rare:Nasal congestion.
Gastrointestinal disorders
Common:Gastrointestinal discomfort with symptoms such as nausea, diarrhea, and abdominal pain, indigestion, vomiting.
Uncommon:Constipation.
Rare:Dry mouth.
Skin and subcutaneous tissue disorders
Uncommon:Cutaneous reactions (e.g. allergic exanthema, dermatitis, urticaria, pruritus, psoriasis, lichen planus-like skin lesions).
Unknown frequency:Hair loss, severe cutaneous adverse reactions (e.g. toxic epidermal necrolysis, Stevens-Johnson syndrome), excessive sweating (hyperhidrosis).
Haematological and lymphatic system disorders
Common:Anemia (decreased red blood cell count).
Rare:Thrombocytopenia (decreased platelet count).
Very rare:Leucopenia (decreased white blood cell count).
Hepatobiliary disorders
Very rare:Alterations in serum transaminases (changes in the amount of certain liver enzymes in the blood).
Eye disorders
Common:Decreased tear production (dry eye), eye irritation, visual disturbances.
Renal and urinary disorders
Common:Acute renal failure (kidney not functioning properly) and renal function disorders in patients with diffuse vascular disease and/or altered renal function.
Rare:Urination problems.
Unknown frequency:Urinary incontinence in women (disappears when stopping medication).
Immune system disorders
Very rare:Allergic reactions.
Musculoskeletal and connective tissue disorders
Common:Limbs pain.
Reproductive and breast disorders
Uncommon:Impotence.
Metabolism and nutrition disorders
Common:Worsening of blood sugar control in diabetic patients (hyperglycemia, hypoglycemia), weight gain, increased blood cholesterol.
Unknown frequency:It is possible that latent diabetes mellitus may manifest, or that existing diabetes may worsen.
General disorders and administration site conditions
Very common:Fatigue.
Common:Pain, edema (fluid retention, swelling of legs, ankles, and feet).
If you consider that any of the side effects you are experiencing is severe or if you notice any side effect not mentioned in this leaflet, inform your doctor or pharmacist.
Reporting of side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through the Spanish System for the Pharmacovigilance of Medicinal Products for Human Use: https://www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keepthis medicationout ofsight andout of reach of children.
Do not store at a temperature above30°C.
Do not usethis medicationafter the expiration date that appears on the packaging after “CAD”. The expiration date is the last day of the month indicated.
Medicines should not be disposed of through drains or in the trash. Dispose of packaging and medicines you no longer need at the SIGRE collection pointat the pharmacy. Ask your pharmacist how to dispose of packaging and medicines you no longer need. By doing so, you will help protect the environment.
Composition of Carvedilol cinfa
Appearance of the product and contents of the packaging
Carvedilol cinfa 6.25 mg is presented in the form of yellow, cylindrical, biconvex, scored tablets on one side and marked with the code “CV6” on the other.
Each package contains 28 or 500 (clinical package) tablets.
Only some package sizes may be marketed.
Holder of the marketing authorization and responsible for manufacturing
Laboratorios Cinfa, S.A.
C arretera Olaz-Chipi, 10. Industrial Park Areta
31620 Huarte (Navarra) - Spain
Last review date of this leaflet: September 2024
Detailed information about this medication is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS) http://www.aemps.gob.es/
You can access detailed and updated information about this medication by scanning the QR code included in the leaflet and packaging with your smartphone. You can also access this information at the following internet address: https://cima.aemps.es/cima/dochtml/p/68327/P_68327.html
QR code to: https://cima.aemps.es/cima/dochtml/p/68327/P_68327.html
Маєте питання щодо цього лікування або ваших симптомів? Зв'яжіться з ліцензованим лікарем для отримання допомоги та персонального догляду.